Palmer J, Messina J, Biletch R, Grosel K, Mahmoud R. Health care for chronic rhinosinusitis (CRS) symptoms—a cross-sectional, population-based survey of US adults meeting symptom criteria for CRS. Poster presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 3-6, 2017; Atlanta, GA.
Data on file, Sanofi US. CSR SAR231893/REGN668, 2018.
Liu T, Cooper T, Earnshaw J, Cervin A. Disease burden and productivity cost of chronic rhinosinusitis patients referred to a tertiary centre in Australia. Aust J Otolaryngol. 2018;1:5. doi:10.21037/ajo.2018.01.03
DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555.
Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-1070.
Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373-377.
Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.
DUPIXENT Prescribing Information.
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
Mechanism of Action
DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling
DUPIXENT is a human monoclonal antibody that specifically binds to the IL-4Rα subunit shared by receptor complexes for IL-4 and IL-138
DUPIXENT inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor
DUPIXENT inhibits IL-4 and IL-13 cytokine-induced inflammatory responses that contribute to8,9:
Eosinophil activation and trafficking
Mast cell activation
See how eligible patients can access
support for DUPIXENT
This site is intended for U.S. Healthcare Professionals only.
Do you wish to continue?
You are leaving a Sanofi US website
Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi hosted US website and going to another, entirely independent, website. Sanofi US and Regeneron provide these links as a service to its website visitors and users; however, they take no responsibility for the information on any website but its own.
US.DUP.16.11.031 | US-DAD-13757
You are about to leave sanofi site for U.S.
Sanofi US does not review the information
contained on this website and/or database
for content, accuracy or completeness. Use
of and access to this information is subject to
the terms, limitations and conditions set by the
website and/or database producer.
This site might not comply with the regulatory requirements of US